Indeed, some of the DDR genes implicated in these experimental studies (e.g., TP53BP1 and MRE11A) have also been observed in PARPi-resistant tumors from patients with BRCA1/2-mutant breast cancer (Waks et al, 2020). This evidence concerns the gene BRCA1 and breast carcinoma.